Giner, Inc.

Giner, Inc., a for-profit Subchapter S corporation headquartered in Auburndale, Massachusetts, develops advanced electrochemical technologies—fuel cells, electrolyzers, batteries, and point-of-care diagnostic sensors—and sells them to federal agencies as a small business prime contractor across SBIR/STTR programs and NASA/DoD/NIH research contracts. The vendor competes exclusively under total small business set-asides on SBIR and STTR vehicles and on full-and-open federal R&D awards; no contract work carries a competitive set-aside designation.

Giner's federal footprint is concentrated in research and development. The top five customer agencies by award count account for 34% of all recent awards: NASA's Shared Services Center (35 awards, $11 million combined potential value), the Department of Health and Human Services National Institutes of Health (24 awards), the Department of the Army (24 awards), the Department of Energy Office of Science (19 awards), and the Department of the Navy (19 awards). By potential value, NASA Shared Services Center anchors the portfolio at $11 million across 35 awards, followed by Army Materiel Command RDEC ($5.9 million, 13 awards) and Air Force Materiel Command Research Laboratory ($3.2 million, 13 awards). Giner serves 57 distinct federal agencies across the portfolio—a broad customer base that reflects the vendor's focus on early-stage research applicable across energy, aerospace, defense, agriculture, and health domains rather than sustained prime relationships on large production vehicles.

Capability work spans energy systems, chemical sensors, and bioelectronics. Representative contracts include a $931 thousand SBIR Phase III regenerative fuel cell development for NASA (August 2025, firm fixed price, 2 kW fuel cell project through June 2027), a $899 thousand Phase II SBIR for lithium-sulfur batteries for electrified aircraft propulsion for NASA (July 2025, through July 2027), a $1.1 million STTR Phase II for rapid multiplexed gene detection assays for the Defense Health Agency (July 2023, through August 2026), a $750 thousand SBIR Phase II for lithium-sulfur batteries for Air Force applications (March 2022, through September 2024), and a $749 thousand NASA grant for non-flow-through fuel cell systems for high-density energy storage (February 2023, through May 2025). Recent federal grant work includes a $591 thousand SBIR Phase I from the National Heart, Lung, and Blood Institute for a portable fractional exhaled nitric oxide breathalyzer for home-based asthma monitoring in children (September 2026), a $181 thousand USDA National Institute of Food and Agriculture SBIR grant for bacteriophage-based antimicrobial product development against bovine mastitis (September 2025), a $306 thousand SBIR Phase I from the National Institute on Drug Abuse for point-of-care HIV viral load and drug adherence assays (September 2024), and an ARPA-E cooperative agreement for dual-recycle CO2-to-ethylene conversion platform development (August 2024, through September 2027). Giner also holds multiple grants from the Department of Energy Office of Science focused on electrolyzer and membrane development for water electrolysis, PFAS remediation via advanced oxidation, and magnesium-ion battery separator membranes. The portfolio reflects a research vendor positioned at the intersection of energy transition, diagnostics, and environmental remediation — not a production or services contractor.

Giner operates as a pure prime contractor on 98% of awards (351 of 357), with minimal subcontractor footprint (6 sub-awards at 2% of total). Across SCI-reportable prime service contracts, the vendor averaged 1% sub-hours share and named only one subcontractor. The federal grant sub-award activity shows Giner supporting as a subawardee under research institutions (Georgia Tech Research Corporation, Columbia University, Ohio University, Cincinnati University) on Phase II ARPA-E and DOE awards for electrolyzer system design, testing, and commercialization pathway work—a typical pattern for specialized hardware vendors embedded in university-led research teams. Giner builds its own delivery teams; it does not function as a feeder for larger primes.

SCI-reported invoiced revenue on federal service contracts above the $150,000 threshold reached $12.4 million across FY2022 through FY2025, with $1.5 million in FY2022, $5.8 million in FY2023, $5 million in FY2024, and zero in FY2025 (reflecting incomplete reporting or contract timing). SCI-reported workforce scaled from 5.0 FTEs in FY2022 to 16.7 in FY2023 and 14.8 in FY2024, indicating modest federal service-contract headcount. Government-paid hourly rates on SCI-reportable contracts ran from a 10th percentile floor of $7.93/hr (likely entry-level or clerical labor) to a median of $137.67/hr and a 90th percentile ceiling of $223.72/hr for senior technical labor—a pricing structure consistent with specialized electrochemistry and advanced diagnostics R&D. SCI is a partial view: it captures only service contracts above $150,000 and excludes the hardware goods (electrolyzers, batteries, sensors) that form the bulk of Giner's federal delivery footprint.

Activity has been variable across the past five years—seven awards in 2022, thirteen in 2023, nine in 2024, eight in 2025, and four in 2026 (through early September). Seven awards totaling $1.8 million in combined potential value reach ultimate completion in the next twenty-four months, presenting modest recompete exposure. Giner holds no named seats on government-wide contract vehicles (GWACs, BPAs, or agency-wide IDIQs); it wins individual SBIR/STTR Phase I, II, and III awards and competitive grants through agency-direct solicitations. The top parent vehicles listed—five Army and Navy IDICs from the early 1980s through 2000s—are legacy from decades-old contracts and represent historical rather than active positions.

The corporate structure includes Giner Electrochemical Systems, LLC as a named subsidiary; the source does not specify its operational or capability role within the parent.

R&D firm specializing in development of proton- exchange membrane (PEM) based electrochemical technologies; electrochemical sensors and biomedical devices as self-contained transdermal alcohol sensors and environmental gas sensors.